


Details:
Under the agreement, AFT will commercialise ZENEO® Midazolam, a combination of the single use needle-free auto injector ZENEO® and the drug product midazolam, in epileptic seizures in Australia and New Zealand.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zeneo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: AFT Pharmaceuticals
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 20, 2023
Details:
ZENEO and the syringe with intramucular needle showed a similar and low inter-subject variability of midazolam pharmacokinetics. This is an additional demonstration that an injection with ZENEO reached muscle in the same way as an injection with a syringe and a 30 mm needle.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zeneo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
DIACOMIT (stiripentol) is an effective treatment for seizures that are often resistant to other antiepileptic drugs. In two clinical studies, DIACOMIT reduced generalized clonic or tonic-clonic seizures by a median of 84% compared with 5.8% on placebo after two months.
Lead Product(s): Stiripentol
Therapeutic Area: Neurology Product Name: Diacomit
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
DIACOMIT (stiripentol), is a molecular entity approved by the FDA for the adjunctive treatment of seizures associated with Dravet syndrome in 2 years of age and older taking clobazam. An orally administered, DIACOMIT is given as either a capsule or powder for suspension.
Lead Product(s): Stiripentol
Therapeutic Area: Neurology Product Name: Diacomit
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: PANTHERx Rare Pharmacy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 27, 2022
Details:
ZENEO's Midazolam is developed as a combination of the single use needle-free auto injector ZENEO and the drug product midazolam, which is an improved anti-convulsant benzodiazepine recommended for treatment of strong seizures resulting from epilepsia.
Lead Product(s): Midazolam
Therapeutic Area: Neurology Product Name: Zeneo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 18, 2022